Who is sponsoring NCT00697567?

NCT00697567 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00697567?

Interventions in NCT00697567: Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant, Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant.

What condition does NCT00697567 study?

NCT00697567 studies Prophylaxis Herpes Simplex.

Is NCT00697567 still recruiting?

NCT00697567 is currently completed. Last updated 13 June 2008.

Last reviewed 2008-06-13 · How we verify

NCT00697567

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study in Healthy HSV Positive and HSV Negative Adults to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Herpes Simplex (gD) Candidate Vaccine With or Without Adjuvant

Completed Phase 2 Last updated 13 June 2008

What this trial tests

Phase 2 trial testing Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant in Prophylaxis Herpes Simplex in 80 participants. Completed in 1 December 1997.

Timeline

1 September 1992

Primary endpoint
1 December 1997

1 December 1997

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	80
Start date	1 September 1992
Primary completion	1 December 1997
Estimated completion	1 December 1997
Sites	1 location across Belgium

Drugs / interventions tested

Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant — full drug profile →
Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant — full drug profile →

Conditions studied

Prophylaxis Herpes Simplex — all drugs for Prophylaxis Herpes Simplex →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 40, any sex, with Prophylaxis Herpes Simplex. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the immunogenicity of herpes simplex vaccine, with or without MPL, in healthy adult HSV seropositive and HSV seronegative volunteers
Time frame: Days 0, 30, 60, 180 and 365 after vaccination
To evaluate the reactogenicity and safety of the MPL-containing and non-MPL-containing vaccine in healthy adult HSV seronegative and seropositive volunteers
Time frame: Reactogenicity from day 0 to day 6 after vaccination. Safety from day 0 to day 365 after vaccination

Sponsor's own description

The purpose of the phase IIa study in healthy HSV seropositive and HSV seronegative adults is to evaluate the immunogenicity, reactogenicity and safety of herpes simplex (gD) candidate vaccine with or without adjuvant administered according to a 0, 1, 6 month schedule.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A review of HSV pathogenesis, vaccine development, and advanced applications.
Bai L, Xu J, Zeng L, Zhang L, et al · · 2024 · cited 30× · PMID 39207577 · DOI 10.1186/s43556-024-00199-7
The Current State of Vaccine Development for Ocular HSV-1 Infection.
Royer DJ, Cohen A, Carr D. · · 2015 · cited 21× · PMID 25983856 · DOI 10.1586/17469899.2015.1004315
Tackling cutaneous herpes simplex virus disease with topical immunomodulators-a call to action.
Duarte LF, Carbone-Schellman J, Bueno SM, Kalergis AM, et al · · 2025 · cited 4× · PMID 39982077 · DOI 10.1128/cmr.00147-24

Verify or expand the search:

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00697567 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 13 June 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00697567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing